Literature DB >> 17172706

DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.

Michel Herranz1, Manel Esteller.   

Abstract

Epigenetics, a combination of DNA modifications, chromatin organization, and variations in its associated proteins, configure a new entity that regulates gene expression throughout methylation, acetylation, and chromatin remodeling. In addition to silencing as a result of mutations, loss of heterozygosity, or classical genetic events epigenetic modification symbolizes essential early events during carcinogenesis and tumor development. The reversion of these epigenetic processes restoring normal expression of tumor-suppressor genes has consequently become a new therapeutic target in cancer treatment. Aberrant patterns of epigenetic modifications will be, in a near future, crucial parameters in cancer diagnosis and prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17172706     DOI: 10.1385/1-59745-208-4:25

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

Review 1.  DNA methylation and microRNAs in cancer.

Authors:  Xiang-Quan Li; Yuan-Yuan Guo; Wei De
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  Targeting tumor suppressor networks for cancer therapeutics.

Authors:  Xuning Emily Guo; Bryan Ngo; Aram Sandaldjian Modrek; Wen-Hwa Lee
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

3.  Revealing epigenetic patterns in gene regulation through integrative analysis of epigenetic interaction network.

Authors:  Jianzhong Su; Yunfeng Qi; Shengqiang Liu; Xueting Wu; Jie Lv; Hongbo Liu; Ruijie Zhang; Yan Zhang
Journal:  Mol Biol Rep       Date:  2011-05-28       Impact factor: 2.316

4.  Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds.

Authors:  Rafael Guerrero-Preston; Lynn R Goldman; Priscilla Brebi-Mieville; Carmen Ili-Gangas; Cynthia Lebron; Frank R Witter; Ben J Apelberg; Marina Hernández-Roystacher; Andrew Jaffe; Rolf U Halden; David Sidransky
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

5.  Application of RUNX3 gene promoter methylation in the diagnosis of non-small cell lung cancer.

Authors:  Gui-Ping Yu; Yong Ji; Guo-Qiang Chen; Bin Huang; Kai Shen; Song Wu; Zhen-Ya Shen
Journal:  Oncol Lett       Date:  2011-10-19       Impact factor: 2.967

6.  DJ-1 is involved in epigenetic control of sphingosine-1-phosphate receptor expression in vascular neointima formation.

Authors:  Kang Pa Lee; Suji Baek; Seung Hyo Jung; Long Cui; Donghyen Lee; Dong-Youb Lee; Wahn Soo Choi; Hyun Woo Chung; Byeong Han Lee; Bokyung Kim; Kyung Jong Won
Journal:  Pflugers Arch       Date:  2018-03-06       Impact factor: 3.657

Review 7.  Epigenetic transgenerational actions of vinclozolin on the development of disease and cancer.

Authors:  Michael K Skinner; Matthew D Anway
Journal:  Crit Rev Oncog       Date:  2007-08

8.  Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes.

Authors:  Amanda M Saratsis; Madhuri Kambhampati; Kendall Snyder; Sridevi Yadavilli; Joseph M Devaney; Brennan Harmon; Jordan Hall; Eric H Raabe; Ping An; Melanie Weingart; Brian R Rood; Suresh N Magge; Tobey J MacDonald; Roger J Packer; Javad Nazarian
Journal:  Acta Neuropathol       Date:  2013-12-03       Impact factor: 17.088

Review 9.  Application of DNA methylation biomarkers for endometrial cancer management.

Authors:  Shi-Wen Jiang; Jinping Li; Karl Podratz; Sean Dowdy
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

10.  HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.

Authors:  Cassandra A Godman; Rashmi Joshi; Brendan R Tierney; Emily Greenspan; Theodore P Rasmussen; Hsin-Wei Wang; Dong-Guk Shin; Daniel W Rosenberg; Charles Giardina
Journal:  Cancer Biol Ther       Date:  2008-10-07       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.